Gastric cancer: epidemiology, prevention, classification, and treatment

R Sitarz, M Skierucha, J Mielko… - Cancer management …, 2018 - Taylor & Francis
Gastric cancer is the second most common cause of cancer-related deaths in the world, the
epidemiology of which has changed within last decades. A trend of steady decline in gastric …

Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?

RR Ramjiawan, AW Griffioen, DG Duda - Angiogenesis, 2017 - Springer
Angiogenesis is defined as the formation of new blood vessels from preexisting vessels and
has been characterized as an essential process for tumor cell proliferation and viability. This …

Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the …

J Li, S Qin, J Xu, J **ong, C Wu, Y Bai, W Liu… - Journal of Clinical …, 2016 - ascopubs.org
Purpose There is currently no standard treatment strategy for patients with advanced
metastatic gastric cancer experiencing progression after two or more lines of chemotherapy …

The impact of hypoxia on immune state in cancer

K Mortezaee, J Majidpoor - Life sciences, 2021 - Elsevier
Hypoxia is a known feature of solid tumors and a critical promoter of tumor hallmarks.
Hypoxia influences tumor immunity in a way favoring immune evasion and resistance …

The Italian Research Group for Gastric Cancer (GIRCG) guidelines for gastric cancer staging and treatment: 2015

G De Manzoni, D Marrelli, GL Baiocchi, P Morgagni… - Gastric Cancer, 2017 - Springer
The Italian Research Group for Gastric Cancer (GIRCG) guidelines for gastric cancer staging
and treatment: 2015 | Gastric Cancer Skip to main content Advertisement SpringerLink Account …

Distinct molecular subtypes of gastric cancer: from Laurén to molecular pathology

M Cisło, AA Filip, GJA Offerhaus, B Ciseł… - …, 2018 - pmc.ncbi.nlm.nih.gov
In Western countries the majority of gastric cancers (GC) are usually diagnosed in advanced
stages reporting a 5-year survival rate of only 26%. The Laurén classification of GC was …

Mechanisms of resistance to chemotherapy in gastric cancer

JJG Marin, R Al-Abdulla, E Lozano… - Anti-Cancer Agents …, 2016 - benthamdirect.com
Although surgical resection is the standard curative therapy for gastric cancer, these tumors
are often diagnosed at an advanced stage, when surgery is not recommended. Alternative …

Targeted therapies for gastric cancer: failures and hopes from clinical trials

M Apicella, S Corso, S Giordano - Oncotarget, 2017 - pmc.ncbi.nlm.nih.gov
Gastric cancer is the third leading cause of cancer mortality worldwide. As surgery is the only
curative treatment strategy and conventional chemotherapy has shown limited efficacy-with …

Molecular targeted drugs and treatment of colorectal cancer: recent progress and future perspectives

F Geng, Z Wang, H Yin, J Yu, B Cao - Cancer biotherapy & …, 2017 - liebertpub.com
Nowadays, colorectal cancer is the fourth most common type of tumor all over the world.
When diagnosed,∼ 50%–60% of tumors have metastasized, thus resulting in a grim …

[HTML][HTML] A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung …

K Yoh, Y Hosomi, K Kasahara, K Yamada, T Takahashi… - Lung cancer, 2016 - Elsevier
Objectives Ramucirumab plus docetaxel prolongs survival in patients with non-small cell
lung cancer (NSCLC) with disease progression after platinum-based therapy. This phase II …